von Willebrand Disease – Managed Care Opportunities to Apply New Guideline-Endorsed Treatment and Patient Management Strategies Web Activity


Christina Barrington, PharmD
VP of Pharmacy Programs
Priority Health

Click here for biography

Angela Weyand, MD
Clinical Assistant Professor, Department of Pediatrics
and Communicable Diseases
University of Michigan

Click here for biography

Maria Lopes, MD, MS
Former Chief Medical Officer
Magellan Health

Click here for biography

Marla Feinstein, MPH, PhD
Senior Policy and Healthcare Analyst
National Hemophilia Foundation

Target Audience

This activity is designed to meet the educational needs of managed care pharmacy directors, clinical pharmacists, quality directors, medical directors, registered nurses, and other managed health care professionals.

Statement of Need/Program Overview 

Bleeding disorders affect more than three million Americans by preventing the blood from clotting normally, potentially leading to prolonged bleeding after injury, surgery, and physical trauma. VWD is the most common bleeding disorder in the United States, although estimates of disease incidence vary significantly. As many as 2 in 100 individuals may be affected by VWD, with a similar frequency in both males and females; however, heavy menstrual bleeding (HMB) and post-partum hemorrhage (PPH) associated with this particular type of bleeding disorder make it more problematic in women. Considering the diverse physical and psychosocial complications associated with VWD, expert disease management is best delivered via the integrated care model implemented by hemophilia treatment centers (HTCs). This model deploys a multidisciplinary team of health care providers to address virtually every facet of care for patients with bleeding disorders.

Educational Objectives 

Accreditation Statement 

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine, National Hemophilia Foundation, and Impact Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for 0.75 contact hours (0.75 CEUs) of the Accreditation Council for Pharmacy Education.

Universal Activity Number: JA4008162-9999-22-084-H01-P
Type of Activity: Knowledge

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.75 contact hours.


Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Name of Faculty Reported Financial Relationship

Christina Barrington, PharmD

Christina Barrington, PharmD has nothing to disclose.

Angela Weyand, MD

Consulting Fees (ex. advisory boards) – Takeda, Genentech, Sanofi, Bayer
Contracted Research – Takeda, Pfizer, Sanofi, Novo Nordisk

Maria Lopes, MD, MS

Maria Lopes, MD, MS has nothing to disclose. 

The PIM planners and managers have nothing to disclose.
The National Hemophilia Foundation planners and managers have nothing to disclose.
The Impact Education, LLC® planners and managers have nothing to disclose.

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

In order to obtain your CE certificate, please follow the steps below at the conclusion of the activity:

For Pharmacists: Upon successfully completing the activity evaluation, you may immediately submit your CPE credit to the NABP CPE Monitor Service. This may require you to add or update the e-profile ID/date of birth information saved in your account. Credit must be uploaded to CPE Monitor within 30 days.

There is no fee for this educational activity.